Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012
Anti-inflammatory asthma therapy adherence in paediatric patients: The PACMAN cohort study Source: Annual Congress 2010 - Management of airway disease Year: 2010
Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Metabolomic approach in the characterization of omalizumab responders and non-responders among children with severe asthma: a multicenter prospective study. Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021
Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015
Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
Efficacy and safety of erdosteine in COPD: Results of a 12-month prospective, multinational study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients Source: Eur Respir J, 58 (6) 2101702; 10.1183/13993003.01702-2021 Year: 2021
BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012
Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study Source: ERJ Open Res, 5 (1) 00175-2018; 10.1183/23120541.00175-2018 Year: 2019
Short-term HRQL deterioration during early-phase COPD exacerbation: a prospective Canadian cohort study Source: Eur Respir J 2005; 26: Suppl. 49, 296s Year: 2005
The APEX study: A retrospective review of outcomes in patients with severe allergic asthma who were or were not hospitalised in the year prior to omalizumab initiation in UK clinical practice Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Benefits of interferon-αcon-1 (IFN-αcon-1) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy. Results of a 12-month prospective case-controlled study Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006
Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010